Due to the increase in the frequency of anaphylactic-type reactions in cattle following the use of the HIPRABOVIS IBR MARKER LIVE vaccine in specific geographical areas of Spain and Italy, the HIPRA Company, in agreement with the European Medicines Agency (EMA) and the National Medicines Agency (EOF), is sending information to animal health professionals.
For the full text of the announcement click here.
